Cardinal Fin Cp (CFNL) 22.08 $CFNL The Zacks Analyst

New Post Public Reply Private Reply Replies (0) Message Board

Jul 10, 2016 at 4:14 PM

Cardinal Fin Cp (CFNL) 22.08 $CFNL

The Zacks Analyst Blog Highlights: First Bancorp, Cardinal Financial, Monarch Financial Holdings, Southern National Bancorp of Virginia and State Bank Financial
Zacks Equity Research - Zacks Investment Research - Tue May 31, 8:30AM CDT
The Zacks Analyst Blog Highlights: First Bancorp, Cardinal Financial, Monarch Financial Holdings, Southern National Bancorp of Virginia and State Bank Financial
CFNL: 22.08 (+0.64), FBP: 4.17 (+0.17), SONA: 12.28 (+0.15), MNRK: 18.49 (-1.37), STBZ: 21.26 (+0.68)

5 Best Southeast U.S. Bank Stocks of the Region
Zacks Equity Research - Zacks Investment Research - Fri May 27, 1:11PM CDT
Economies of some of the regions look favorable for their resident banks. So these banks might be able to deal with the broader issues better than others. One such region is the Southeast.
CFNL: 22.08 (+0.64), FBP: 4.17 (+0.17), SONA: 12.28 (+0.15), MNRK: 18.49 (-1.37), STBZ: 21.26 (+0.68)

If the Fed Raises Interest Rates, Buy These 3 Banking Stocks
Zacks Premium Research - Zacks Investment Research - Wed May 25, 3:06PM CDT
These stocks are well-positioned with regards to surpassing investor expectations.
BANC: 18.41 (+0.16), CFNL: 22.08 (+0.64), FBP: 4.17 (+0.17)

Cardinal Financial Corporation Declares Quarterly Dividend
BusinessWire - Thu Apr 21, 9:04AM CDT
Cardinal Financial Corporation (NASDAQ: CFNL) (the "Company"

today announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share. This dividend will be paid on May 20, 2016 to shareholders of record as of the close of business on May 5, 2016.
CFNL: 22.08 (+0.64)

Cardinal Financial tops Street 1Q forecasts
Automated Insights - Wed Apr 20, 12:09PM CDT
MCLEAN, Va. (AP) _ Cardinal Financial Corp. (CFNL) on Wednesday reported first-quarter net income of $13.1 million.
CFNL: 22.08 (+0.64)

Cardinal Announces First Quarter 2016 Earnings
BusinessWire - Wed Apr 20, 11:46AM CDT
Cardinal Financial Corporation (NASDAQ: CFNL) (the "Company"

today reported that earnings for the quarter ended March 31, 2016 were $13.1 million, compared to $9.0 million for the previous quarter ended December 31, 2015 and $13.7 million for the year ago quarter ended March 31, 2015. Diluted earnings per share were $0.39, $0.27 and $0.42 for these same respective periods.
CFNL: 22.08 (+0.64)

Cardinal Bank Names Local Businessman Nick Carosi as Honorary Chair of its 2016 Cardinal Charity Classic
BusinessWire - Thu Mar 03, 10:21AM CST
Cardinal Bank (NASDAQ: CFNL) is pleased to announce that Nick Carosi III has been named Honorary Chairman of its 2016 Annual Charity Classic benefiting Inova Kellar Center and the Cardinal Community Fund. Carosi is President and CEO of Arban & Carosi and Chairman of the Inova Health System Board of Trustees.
CFNL: 22.08 (+0.64)

19.7% Return Seen to Date on SmarTrend Cardinal Financial Call (CFNL)
Comtex SmarTrend(R) - Fri Feb 05, 6:10PM CST
SmarTrend identified a Downtrend for Cardinal Financial (NASDAQ:CFNL) on December 11th, 2015 at $22.90. In approximately 2 months, Cardinal Financial has returned 19.65% as of today's recent price of $18.40.
CFNL: 22.08 (+0.64)

Downtrend Call Working As Cardinal Financial Stock Falls 18.5% (CFNL)
Comtex SmarTrend(R) - Fri Jan 29, 5:36PM CST
SmarTrend identified a Downtrend for Cardinal Financial (NASDAQ:CFNL) on December 11th, 2015 at $22.90. In approximately 2 months, Cardinal Financial has returned 18.47% as of today's recent price of $18.67.
CFNL: 22.08 (+0.64)

Cardinal Financial Down 18.8% Since SmarTrend Downtrend Call (CFNL)
Comtex SmarTrend(R) - Fri Jan 22, 12:47PM CST
SmarTrend identified a Downtrend for Cardinal Financial (NASDAQ:CFNL) on December 11th, 2015 at $22.90. In approximately 1 month, Cardinal Financial has returned 18.82% as of today's recent price of $18.59.
CFNL: 22.08 (+0.64)

Upgrade Alert for Cardinal Financial (CFNL)
Comtex SmarTrend(R) - Fri Jan 22, 8:05AM CST
Cardinal Financial (NASDAQ:CFNL) was upgraded from Market Perform to Outperform at Keefe Bruyette today. The stock closed yesterday at $17.99 on volume of 496,000 shares, above average daily volume of 193,000. Cardinal Financial share prices have moved between a 52-week high of $24.99 and a 52-week low of $17.62 and closed yesterday at 2% above that low price at $17.99 per share. The 200-day and 50-day moving averages have moved 0.06% lower and 1.16% lower over the past week, respectively.
CFNL: 22.08 (+0.64)

Cardinal Financial announces dividend of USD0.12 per share for quarter
M2 - Thu Jan 21, 6:05AM CST
The board of directors of Cardinal Financial Corporation (NASDAQ:CFNL) approved a cash dividend of USD0.12 per share, the company reported on Thursday.
CFNL: 22.08 (+0.64)

Cardinal Financial misses Street 4Q forecasts
Automated Insights - Wed Jan 20, 12:34PM CST
MCLEAN, Va. (AP) _ Cardinal Financial Corp. (CFNL) on Wednesday reported fourth-quarter earnings of $9 million.
CFNL: 22.08 (+0.64)

Roadmap to Our Regions Economic Future
BusinessWire - Mon Jan 11, 3:28PM CST
Cardinal Bank (NASDAQ:CFNL) announced that it will host the 24th Annual Economic Conference in partnership with Northern Virginia Chamber of Commerce, George Mason University and the Washington Business Journal.
CFNL: 22.08 (+0.64)

Cardinal Bank announces addition of Apple Pay to its mobile services for purchases
M2 - Mon Jan 11, 6:02AM CST
Cardinal Bank (NASDAQ:CFNL) revealed on Saturday that its consumer and business clients will have access Apple Pay to make purchases using their debit and credit cards.
CFNL: 22.08 (+0.64)

Cardinal Bank adds Apple Pay (TM)to its Mobile Services
BusinessWire - Fri Jan 08, 3:30PM CST
Cardinal Bank (NASDAQ: CFNL) announced today its consumer and business clients will now have access to make purchases with Apple Pay using their Cardinal Bank debit and credit cards. This new service transforms mobile payments with an easy, secure and private way to pay for purchases.
CFNL: 22.08 (+0.64)

Bank of Ozarks Ups Dividend: Is this the Right Time to Buy?
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 2:20PM CST
Bank of the Ozarks (OZRK) hikes quarterly dividend again. Should you add the stock to your portfolio now?
FCB: 34.41 (+0.71), CFNL: 22.08 (+0.64), CBF: 29.10 (+0.89), OZRK: 36.78 (+1.31)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alaska's Insurance Maze: Coverage Over Cheap Policies

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Apalutamide Boosts Outlook for Prostate Cancer Treatment

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Darden Faces Class Action Over Reimbursement Failures

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...